Suchergebnisse - "Ruof, J"

PubPharm (79)

1

Review of Relative effectiveness assessments (REAs) of pharmaceuticals at the European network for health technology assessment (EUnetHTA) : A first step towards a consolidated European perspective on comparative effectiveness & safety?

enthalten in: Health policy (Amsterdam, Netherlands) | 2020

von Chassagnol, F. | Marcelli, G. | Wagle, J. | +4

2

Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany : whenever IQWiG and Federal Joint Committee disagree

enthalten in: Health economics review | 2019

von Dintsios, C. | Worm, F. | Ruof, J. | +1

3

Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree

enthalten in: Health economics review | 2019

von Dintsios, C. | Worm, F. | Ruof, J. | +1

4

Recommendations In Clinical Guidelines, ‘No Benefit’ Ratings, And Opt-Out Decisions In Germany Since The Introduction Of The Amnog Law In 2011: How Do The Pieces Fit Together?

enthalten in: Value in health | 2016

von Staab, T. | Dintsios, C. | Schulenburg, J. | +1

5

Acceptance of Clinically Relevant Primary Study Endpoints In The German Health Technology Assessment Process: Analysis of Five Different Disease Areas

enthalten in: Value in health | 2015

von Isbary, G. | Ruof, J. | Staab, T. | +1

6

G-Ba Does not Adjust Evidence Requirements in Early Benefit Assessment in Cases of Pre-Defined, Efficacy-Based Cross-Over Decisions in Oncology Trials

enthalten in: Value in health | 2015

von Dintsios, C. | Isbary, G. | Staab, T. | +2

7

Comparison of Post-Authorisation Measures From Regulatory Authorities With Additional Evidence Requirements From HTA Bodies in Germany

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2014

von Ruof, J. | Staab, T. | Slawik, L. | +2

8

The Risky Business of Drug Development : The Final Say of National Hta Agencies on A Pharmaceutical's Benefit During The Last Stretch of An Expensive, Long-Lasting And Arduous Development Journey - As Illustrated By The Decisions Of Germany's Gemeinsamer Bundesausschuss (G-Ba)

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2014

von Maetzel, A. | Staab, T. | Ruof, J.

9

Dilemma of Cross-Over Trials and Their Impact on Benefit Assessment In Oncology

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2014

von Ruof, J. | Staab, T. | Walter, M.

10

Comparison of Post-Authorisation Measures From Regulatory Authorities With Additional Evidence Requirements From HTA Bodies in Germany

enthalten in: Value in health | 2014

von Ruof, J. | Staab, T. | Slawik, L. | +2

1
2
3
4
5
6
7
8
Nächster »
[8]